Zacks Gives Neutral Rating to Covidien plc (COV)
Covidien plc (NYSE: COV)‘s stock had its “neutral” rating reaffirmed by Zacks in a research note issued on Monday. They currently have a $58.00 price target on the stock.
A number of other analysts have also recently weighed in on COV. Analysts at Bank of America (NYSE: BAC) raised their price target on shares of Covidien plc from $61.00 to $64.00 in a research note to investors on Monday. They now have a “buy” rating on the stock. Separately, analysts at Morgan Stanley (NYSE: MS) raised their price target on shares of Covidien plc from $56.00 to $61.00 in a research note to investors on Monday. Finally, analysts at Citigroup (NYSE: C) raised their price target on shares of Covidien plc from $60.00 to $64.00 in a research note to investors on Monday.
Shares of Covidien plc opened at 55.23 on Monday. Covidien plc has a one year low of $41.35 and a one year high of $57.65. The company has a market cap of $26.695 billion and a P/E ratio of 14.09.
The company last announced its quarterly results on Friday, April 27th. It reported $1.05 earnings per share (EPS) for the previous quarter, beating the Thomson Reuters consensus estimate of $1.03 EPS by $0.02. The company’s quarterly revenue was up 5.2% on a year-over-year basis. Analysts expect that Covidien plc will post $1.07 EPS next quarter.
Covidien Public Limited Company is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings.